Search for: "Par Pharmaceutical, Inc." Results 81 - 100 of 172
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
15 Sep 2011, 5:46 am by Ray Mullman
Attorney's office joined in the lawsuit, brought by Chicago pharmacist Bernard Lisitza in a 162-page complaint  Defendants include Par Pharmaceuticals Companies Inc. of Woodcliff Lake, N.J., and two foreign generic drugmakers overcharged the Medicaid program by getting pharmacies to dispense different, more-expensive, dosage forms than what was prescribed. [read post]
2 Dec 2009, 11:05 am by dbmadmin
On December 2, 2009, the FTC announced an order settling charges that Watson Pharmaceuticals, Inc. [read post]
7 Oct 2009, 9:59 pm
Sanofi originally filed suit against Sun, Sandoz, Actavis Inc., and Par Pharmaceutical Inc., among other generic manufacturers, in June 2007, accusing them of infringing Sanofi's patent covering Eloxatin ®, U.S. [read post]
7 Feb 2013, 10:50 am by Lawrence B. Ebert
Par Pharmaceutical, Inc., 694 F.3d 1344, 1351 (Fed. [read post]
22 Apr 2009, 6:14 am
Citigroup has been hit with a $30 million auction-rate securities lawsuit filed by Braintree Laboratories, Inc., a specialty pharmaceutical company, reported Christine Caufield in an April 17, 2009 article posted on Law360.com. [read post]
13 Sep 2013, 7:43 am
Coming in "third place" was Par Pharmaceuticals based in Woodcliff Lake, New Jersey. [read post]
3 Nov 2014, 9:48 am by Bruce Colbath
Hospira, Inc.,[2] Par Sterile Products (formerly JHP Pharmaceuticals), a manufacturer of ADRENALIN, an FDA-approved injectable epinephrine product, brought Lanham Act claims against several defendants, American Regent Inc., Hospira Inc. and International Medical Systems, Ltd. [read post]
12 Oct 2009, 12:38 pm
Citigroup Global Market, Inc. has filed a motion to dismiss an action against it by KV Pharmaceuticals Co. arising out of sales of auction rate securities, according to an August 25 article in Law360 by Christine Caufield entitled "Citigroup Argues KV Pharma Knew ARS Risks. [read post]
21 May 2013, 2:26 pm by Fraud Fighters
Earlier this month, the Department of Justice announced a $500 million settlement it reached with Ranbaxy USA Inc., a subsidiary of the Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited. [read post]